Unresectable or metastatic melanoma as a single agent or in combination with ipilimumab; adjuvant treatment of melanoma with involvement of lymph nodes or metastatic disease in patients who have undergone complete resection; neoadjuvant treatment of resectable NSCLC in combination with platinum-doublet chemotherapy; in combination with ipilimumab, for first-line treatment of metastatic NSCLC in patients whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test with no EGFR or ALK genomic tumor aberrations; in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, first-line treatment of metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations; treatment of metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo; in combination with ipilimumab, for first-line treatment of unresectable malignant pleural mesothelioma; in combination with ipilimumab, for first-line treatment of intermediate or poor-risk advanced renal-cell carcinoma (RCC); in combination with cabozantinib, for first-line treatment of advanced RCC; as a single agent for treatment of advanced RCC in patients who have received prior anti-angiogenic therapy; treatment of classical Hodgkin lymphoma that has relapsed or progressed after either autologous HSCT and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous HSCT; treatment of recurrent or metastatic squamous-cell carcinoma of the head and neck with disease progression on or after platinum-based therapy; adjuvant treatment of urothelial carcinoma in patients who are at high risk of recurrence after undergoing radical resection; treatment of locally advanced or metastatic urothelial carcinoma in patients who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy; as a single agent or in combination with ipilimumab for treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; in combination with ipilimumab, for the treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib; adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy; in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of unresectable advanced or metastatic esophageal squamous-cell carcinoma (ESCC); in combination with ipilimumab, for first-line treatment of unresectable advanced or metastatic ESCC; treatment of unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy; in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

Multiple myeloma, in combination with dexamethasone or as maintenance after autologous hematopoietic stem-cell transplant; transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q; mantle-cell lymphoma in patients whose disease relapsed or progressed after 2 therapies, including bortezomib; previously treated follicular lymphoma, in combination with rituximab-containing therapy; previously treated marginal-zone lymphoma, in combination with rituximab-containing therapy

Treatment of unresectable or metastatic melanoma in patients ≥12 years; treatment of unresectable or metastatic melanoma in adult patients in combination with nivolumab; adjuvant treatment of patients with cutaneous melanoma and involvement of regional lymph nodes >1 mm after complete resection, including total lymphadenectomy; first-line treatment of intermediate- or poor-risk advanced renal-cell carcinoma, in combination with nivolumab; treatment of patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer progressing after fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab; treatment of hepatocellular carcinoma after sorafenib therapy, in combination with nivolumab; first-line treatment of metastatic NSCLC expressing PD-L1 (≥1%), as determined by an FDA-approved test, and no EGFR or ALK genomic tumor aberrations, in combination with nivolumab; first-line treatment, in combination with 2 cycles of platinum-doublet chemotherapy and nivolumab, of metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations; first-line treatment of adults with unresectable malignant pleural mesothelioma, in combination with nivolumab; in combination with nivolumab for first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma